Association between hematologic response to iron therapy and risk of stillbirth in pregnant singletons with moderate iron deficiency anemia

The authors aimed to investigate the association between the hematologic response to iron therapy and the risk of stillbirth and other adverse perinatal outcomes in pregnant women with moderate iron deficiency anemia. Their analysis of data from a multicenter trial found that inadequate improvement in hemoglobin levels at 20-24 weeks gestation was linked to an increased risk of stillbirth and early preterm birth, suggesting the importance of early screening and treatment for maternal anemia to prevent adverse outcomes.